China: In a new study conducted by Ying Cao and the team, it was shown that chemiluminescence immunoassay (CLIA) newly created technique has a lot of promise for usage in the clinic. In IBD patients, elevated serum OSM expression was a possible biomarker of severe illness and infliximab non-response. The findings of this study were published in the journal Clinical Biochemistry on 11th November 2021.
Although endoscopy is the gold standard for assessing disease activity and infliximab effectiveness in inflammatory bowel disease (IBD), the invasive, expensive, and time-consuming technique restricts its frequent use. The purpose of this study was to look at the clinical use of serum oncostatin M (OSM) as a surrogate biomarker.
In this study, fifty healthy controls, 34 non-IBD patients, and 189 IBD patients on pre-infliximab therapy (n=122) or infliximab maintenance (n=67) were recruited in this study. To measure serum OSM concentrations, a chemiluminescence immunoassay (CLIA) was developed. The performance of blood biomarkers for IBD treatment was evaluated using receiver operator characteristic (ROC) curve analysis.
The results highlighted that;
CLIA approach demonstrated excellent analytical performance, with a broad linear range of 31.25-25000 pg/mL, a low detection limit of 23.2 pg/mL, acceptable precision, and appropriate accuracy.
Serum OSM levels were greater in IBD and non-IBD patients than in healthy controls.
Serum OSM levels were higher in moderate and severe patients compared to those in remission, according to a study of clinical and endoscopic activity.
IBD patients who did not repair their mucosa exhibited greater serum OSM levels than those who did heal their mucosa. Furthermore, serum OSM levels were higher in clinical non-responders than in responders, indicating a high recognition capacity with an AUC of 0.898.
In conclusion, the authors added, "The newly created CLIA approach demonstrated considerable potential for usage in the clinic. In IBD patients, elevated serum OSM expression was a potential indicator of severe illness and infliximab non-response."
Reference:
Cao Y, Dai Y, Zhang L, Wang D, Yu Q, Hu W, Wang X, Yu P, Ping Y, Sun T, Sang Y, Liu Z, Chen Y, Tao Z. Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay. Clin Biochem. 2021 Nov 26:S0009-9120(21)00310-6. doi: 10.1016/j.clinbiochem.2021.11.011.